ATE382148T1 - Antikörper für apoptosemarker und anwendungsverfahren - Google Patents

Antikörper für apoptosemarker und anwendungsverfahren

Info

Publication number
ATE382148T1
ATE382148T1 AT99948459T AT99948459T ATE382148T1 AT E382148 T1 ATE382148 T1 AT E382148T1 AT 99948459 T AT99948459 T AT 99948459T AT 99948459 T AT99948459 T AT 99948459T AT E382148 T1 ATE382148 T1 AT E382148T1
Authority
AT
Austria
Prior art keywords
antibodies
methods
apoptosis
application
apoptosis markers
Prior art date
Application number
AT99948459T
Other languages
English (en)
Inventor
Terry Riss
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Application granted granted Critical
Publication of ATE382148T1 publication Critical patent/ATE382148T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99948459T 1998-09-24 1999-09-24 Antikörper für apoptosemarker und anwendungsverfahren ATE382148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10192098P 1998-09-24 1998-09-24

Publications (1)

Publication Number Publication Date
ATE382148T1 true ATE382148T1 (de) 2008-01-15

Family

ID=22287166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948459T ATE382148T1 (de) 1998-09-24 1999-09-24 Antikörper für apoptosemarker und anwendungsverfahren

Country Status (6)

Country Link
US (3) US6350452B1 (de)
EP (1) EP1116029B1 (de)
AT (1) ATE382148T1 (de)
AU (1) AU6162999A (de)
DE (1) DE69937835T2 (de)
WO (1) WO2000017648A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
DE69937835T2 (de) * 1998-09-24 2009-01-02 Promega Corp., Madison Antikörper für apoptosemarker und anwendungsverfahren
AU2951801A (en) * 2000-01-12 2001-07-24 Ventana Medical Systems, Inc. Method for quantitating a protein by image analysis
ATE311595T1 (de) * 2000-07-21 2005-12-15 Evotec Ag Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US6982152B2 (en) * 2002-04-17 2006-01-03 Promega Corporation Cytotoxicity assay
WO2004003554A1 (en) * 2002-06-26 2004-01-08 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
FR2863053B1 (fr) * 2003-11-28 2007-04-06 Univ Claude Bernard Lyon Nouvelles sondes hybrides a luminescence exaltee
CN1316037C (zh) * 2003-12-19 2007-05-16 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
CN102605066A (zh) * 2004-12-08 2012-07-25 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070190580A1 (en) * 2005-10-31 2007-08-16 Beckman Coulter, Inc. Immunoassay of Fragments of Insulin-Like Growth Factor Binding Proteins
EP2044434B1 (de) 2006-06-20 2015-11-18 Genentech, Inc. Methoden und materialien zum nachweis von apoptose durch nachweis von fragmenten von komponenten der clathrin-abhängigen endozytose
US20090221004A1 (en) * 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
WO2010021822A2 (en) 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2012061732A1 (en) 2010-11-05 2012-05-10 Cell Signaling Technology, Inc. Motif-specific and context-independent antibodies to a cleaved caspase motif or a sumoylated lysine-containing motif
WO2012167173A1 (en) 2011-06-02 2012-12-06 The University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
WO2012177755A1 (en) * 2011-06-20 2012-12-27 Bioscale, Inc. Methods and systems for the rapid characterization of functional biological molecules
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
CN110563840B (zh) * 2019-04-07 2021-06-01 北京利德曼生化股份有限公司 抗甘胆酸单克隆抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4927916A (en) 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
AU635008B2 (en) 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US5736348A (en) 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
US5387504A (en) * 1992-09-30 1995-02-07 Merck & Co., Inc. Monospecific antibodies and assay system for detecting stromelysin cleavage products
NZ277946A (en) * 1993-11-30 1998-03-25 Lxr Biotechnology Inc Apoptosis modulating protein and nucleotide sequence compositions using bcl-2 homologs termed cdn-1, cdn-2 and cdn3
US5536639A (en) 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US5594116A (en) 1995-11-08 1997-01-14 Promega Corporation Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
WO1998052297A2 (en) 1997-05-15 1998-11-19 Spectraplex, Inc. Parallel transmission method with diverse physical channel allocation
WO1998052597A1 (en) * 1997-05-19 1998-11-26 Chiron Corporation Apoptosis-inducing gelsolin sequences
JP4372340B2 (ja) * 1997-09-30 2009-11-25 ペビバ、アクチボラグ アポトーシス関連化合物およびその使用
DE69937835T2 (de) * 1998-09-24 2009-01-02 Promega Corp., Madison Antikörper für apoptosemarker und anwendungsverfahren
FR2785053A1 (fr) 1998-10-21 2000-04-28 Centre Nat Rech Scient Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) et de detection de l'activite inhibitrice ou activatrice d'un inhibiteur ou d'un activateur de cette enzyme
EP1173486A1 (de) * 1999-04-15 2002-01-23 Merck Frosst Canada & Co. Antikörper, die durch caspase gespaltenes app erkennen und verfahren ihrer anwendung

Also Published As

Publication number Publication date
DE69937835T2 (de) 2009-01-02
US20060166294A1 (en) 2006-07-27
EP1116029A4 (de) 2004-12-15
WO2000017648A1 (en) 2000-03-30
US6350452B1 (en) 2002-02-26
US7037664B2 (en) 2006-05-02
EP1116029B1 (de) 2007-12-26
AU6162999A (en) 2000-04-10
US20020102268A1 (en) 2002-08-01
DE69937835D1 (de) 2008-02-07
EP1116029A1 (de) 2001-07-18

Similar Documents

Publication Publication Date Title
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
DK0921395T3 (da) Assays til måling af proteinfragmenter i biologiske medier
DE602004019812D1 (de) Marker für neuromyelitis optica
ATE458831T1 (de) Verfahren zum nachweis von lungenneoplasmen in fäkalen proben
IS5547A (is) Forlyf fyrir tálma við aspartílprótínkljúfum
BR9508151A (pt) Oligopeptídeo testes para determinar a atividade proteolítica de antígeno livre específico para próstata em uma amostra e para identificar compostos que inibem atividade proteolítica de antígeno específico para próstata e conjugado
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
DK1137943T3 (da) Fremgangsmåde til påvisning af cancer og reagenser
DE60226271D1 (de) Verfahren zum nachweis von prostatakrebs
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE378404T1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
DE602004026888D1 (de) Kinase- und phosphatasetests
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DK1336109T3 (da) Kit og fremgangsmåde til at påvise proteinet EMS-1
ATE389881T1 (de) Detektion von kleinen molekülen mit piezo- elektrischem sensor
EA200200435A1 (ru) Анализ лептина
DE60234465D1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
TW200700089A (en) Recombinant protein comprising starch binding domain and use thereof
DE60229043D1 (de) Rearrangierte plattenepithelkarzinomantigen-gene ii
ATE247831T1 (de) Verfahren zum nachweis von autoimmun-pathologien
DE60331414D1 (de) Aggrecanase-1- und -2-peptidsubstrate und verfahren
WO2004070389A8 (en) Assay for protein isoforms
WO1999038975A3 (en) Polynucleotide and polypeptide sequences associated with cns depressant sensitivity and methods of use thereof
IL151564A0 (en) Potassium channel proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1116029

Country of ref document: EP

REN Ceased due to non-payment of the annual fee